Program
Rimonabant
Also written as “rimonabant (SR141716)”, “Rimonabant (SR141716)” and “rimonabant”.
Its studies are mostly in Obesity · Diabetes Mellitus, Type 2 · Smoking Cessation · Fatty Liver · Post-Acute COVID-19 Syndrome, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sanofi | 350 open or running | phase 3since Jan 23, 2002 | Jan 23, 2002 | none ahead |
| Sinfatin S.L | 33 open or running | phase 2since May 20, 2026 | May 20, 2026 | Aug 2027phase 2 · NCT07843108 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 15 studies since Jan 23, 2002.
- Dec 5, 20062 phase 3 studies in ObesitySanofi · NCT00408148, NCT00412698
- Feb 9, 2007Phase 3 study in ObesitySanofi · NCT00434096 · 915 enrolled · Japan
- Mar 19, 2007Phase 3 study in Diabetes Mellitus, Type 2Sanofi · NCT00449605 · 508 enrolled · United States, Chile, Denmark and more
- Apr 6, 20075 phase 3 studiesSanofi · NCT00458081, NCT00459173, NCT00458718 and 2 more
- Apr 10, 2007Phase 2 study in ObesitySanofi · NCT00459004 · 527 enrolled · Japan
- May 24, 20072 phase 3 studies in ObesitySanofi · NCT00478972, NCT00478595
- Jun 1, 20072 phase 3 studies in ObesitySanofi · NCT00481975, NCT00481923
- Oct 17, 2007Phase 3 study in Diabetes Mellitus, Type 2Sanofi · NCT00546325 · 358 enrolled · Australia
- Dec 18, 20072 phase 3 studies in Fatty LiverSanofi · NCT00577148, NCT00576667
- May 7, 20082 phase 3 studiesSanofi · NCT00690456, NCT00678483
- Sep 17, 2008Phase 3 study in Diabetes Mellitus, Type 2Sanofi · NCT00754689 · United States
- May 20, 2026Sinfatin S.L's first study: phase 2 study in FatigueNew to Sinfatin S.LSinfatin S.L · NCT07843108 · 8 enrolled · Spain
- Oct 27, 2026Phase 2 study in Chronic StrokeSinfatin S.L · NCT07913763 · 80 planned · Spain
- Nov 3, 2026Phase 2 study in Post-Acute COVID-19 SyndromeSinfatin S.L · NCT07930637 · 80 planned · Spain
Ahead
- Aug 2027Primary completion: phase 2 study in FatigueSinfatin S.L · NCT07843108
- Jan 31, 2028Primary completion: phase 2 study in Chronic StrokeSinfatin S.L · NCT07913763
- Mar 2028Primary completion: phase 2 study in Post-Acute COVID-19 SyndromeSinfatin S.L · NCT07930637
TargetBeta
“Cannabinoid CB1 receptor antagonist”ChEMBL 37, by rule
Other programs on CNR1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Cannabidiolrule | Jazz Pharmaceuticals | phase 4 | 68 |
| Dronabinolrule | Jazz Pharmaceuticals | phase 3 | 20 |
| CRB-913rule | corbus-pharmaceuticals-inc | phase 1 | 1 |
Studies
All 38 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07930637Post-Acute COVID-19 Syndrome · Spain | 2 | Not yet recruiting | Sinfatin S.L | Mar 2028 | 80 |
| NCT07913763Chronic Stroke · Spain | 2 | Not yet recruiting | Sinfatin S.L | Jan 31, 2028 | 80 |
| NCT07843108Fatigue · Spain | 2 | Active, not recruiting | Sinfatin S.L | Aug 2027 | 8 |
| NCT00754689Diabetes Mellitus, Type 2 · United States | 3 | Withdrawn | Sanofi | Nov 2008 | 0 |
| NCT00678483Obesity · Croatia, Finland, Hungary and more | 3 | Terminated | Sanofi | Nov 2008 | 331 |
| NCT00690456Diabetes Mellitus, Type 2 · United States, Indonesia, Lithuania and more | 3 | Terminated | Sanofi | Feb 2009 | 403 |
| NCT00577148Fatty Liver · United States, Argentina, Australia and more | 3 | Terminated | Sanofi | Feb 2009 | 89 |
| NCT00576667Fatty Liver · United States, Argentina, Australia and more | 3 | Terminated | Sanofi | Feb 2009 | 165 |
| NCT00546325Diabetes Mellitus, Type 2 · Australia | 3 | Completed | Sanofi | Feb 2009 | 358 |
| NCT00481975Obesity · United States, Finland, France and more | 3 | Completed | Sanofi | Aug 2005 | 289 |
| NCT00481923Obesity · United Kingdom | 3 | Completed | Sanofi | Apr 2005 | 156 |
| NCT00478972Obesity · Japan | 3 | Terminated | Sanofi | Jan 2009 | 321 |
| NCT00478595Obesity · Japan | 3 | Terminated | Sanofi | Feb 2009 | 458 |
| NCT00464256Smoking Cessation · United States | 3 | Completed | Sanofi | Nov 2004 | 533 |
| NCT00464165Smoking Cessation · Belgium, Denmark, France and more | 3 | Completed | Sanofi | Oct 2003 | 789 |
| NCT00459173Maintenance of Smoking Cessation · United States, Australia, Canada | 3 | Completed | Sanofi | Sep 2005 | 4,850 |
| NCT00459004Obesity · Japan | 2 | Completed | Sanofi | Apr 2006 | 527 |
| NCT00458718Smoking Cessation · United States | 3 | Completed | Sanofi | Jul 2005 | 755 |
| NCT00458081Obesity · Spain | 3 | Terminated | Sanofi | Jan 2009 | 174 |
| NCT00449605Diabetes Mellitus, Type 2 · United States, Chile, Denmark and more | 3 | Terminated | Sanofi | Nov 2008 | 508 |
| NCT00434096Obesity · Japan | 3 | Terminated | Sanofi | Nov 2008 | 915 |
| NCT00412698Obesity · Czech Republic, Finland, Germany and more | 3 | Terminated | Sanofi | Jan 2009 | 645 |
| NCT00408148Obesity · Australia, Finland, France and more | 3 | Terminated | Sanofi | Dec 2008 | 64 |
| NCT00405808Obesity · Austria, Belgium, Brazil and more | 3 | Terminated | Sanofi | Feb 2009 | 2,666 |
| NCT00386061Obesity · United States, Belgium, Finland and more | 3 | Completed | Sanofi | Jun 2004 | 1,507 |
| NCT00358228Smoking Cessation · United States | 3 | Completed | Sanofi | Aug 2003 | 787 |
| NCT00325650Prediabetic State · United States | 3 | Terminated | Sanofi | Mar 2009 | 2,420 |
| NCT00325546Obesity · China, Korea, Republic of, Taiwan | 3 | Completed | Sanofi | Apr 2007 | 643 |
| NCT00299325Metabolic Syndrome · United States, Canada, Denmark and more | 3 | Completed | Sanofi | Jul 2008 | 254 |
| NCT00288236Diabetes Mellitus, Type 2 · United States, Argentina, Australia and more | 3 | Completed | Sanofi | Jul 2007 | 368 |
| NCT00263042Cardiovascular Diseases · United States, Argentina, Australia and more | 3 | Terminated | Sanofi | Apr 2009 | 18,695 |
| NCT00257257Diabetes Mellitus, Type 2 · United States, Argentina, Chile and more | 3 | Completed | Sanofi | Jun 2006 | 281 |
| NCT00239967Dyslipidemias · United States, Australia, Brazil and more | 3 | Completed | Sanofi | Feb 2007 | 803 |
| NCT00228176Carotid Stenosis · United States, Canada, France and more | 3 | Terminated | Sanofi | Apr 2009 | 661 |
| NCT00124332Coronary Artery Disease · United States, Australia, Belgium and more | 3 | Completed | Sanofi | Oct 2007 | 839 |
| NCT00029861Obesity · United States, Canada | 3 | Completed | Sanofi | Apr 2004 | 3,045 |
| NCT00029848Obesity · United States, Argentina, Belgium and more | 3 | Completed | Sanofi | May 2004 | 1,045 |
| NCT00029835Obesity · United States, Australia, Canada and more | 3 | Completed | Sanofi | Nov 2003 | 1,033 |
How it is read
Names in the registry
- “Rimonabant”, 19 entries
- “rimonabant (SR141716)”, 8 entries
- “Rimonabant (SR141716)”, 8 entries
- “rimonabant”, 3 entries
Conditions, from the studies’ own filings
- Obesity, 16 studies
- Diabetes Mellitus, Type 2, 6 studies
- Smoking Cessation, 5 studies
- Fatty Liver, 2 studies
- Post-Acute COVID-19 Syndrome, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.